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Pathogen-associated molecular patterns (PAMP) are conserved structural motifs 
recognized by the immune system as foreign.  The recognition of these motifs from 
invading microbes is a first step in priming the immune system and leads to eventual 
clearance of pathogens.  Previous work has shown that an N-terminal truncation of a type 
three secretion needle, YscF, was pro-inflammatory in vivo in a mouse model of Yersinia 
pestis infection (1).  Also, macrophages elicited an inflammatory response after exposure 
to the protein suggesting activity as a PAMP.  This thesis shows data expanding on YscF 
and other needle homolog proteins and their pro-inflammatory effect in macrophage 
tissue culture.  The characterization of the pro-inflammatory effect of these proteins gives 
potential of use as an adjuvant product in vaccines.
Yersinia pestis
Y. pestis is the causative agent of the plague.  This is a disease of particularly 
severe virulence, with widespread notoriety as a human pathogen.  This gram-negative 
bacterium has acquired its reputation over multiple pandemics through history, with 
estimates of 200 million deaths in total (2).  The bacterium resides in enzootic reservoirs 
throughout the world, and has potential to be a deadly biological weapon.  Despite the 
threat of bioterrorism, there is no vaccine currently available for the plague (3).
1
Clinical presentation
Y. pestis manifests itself in three distinct forms in a human infection; bubonic, 
septicemic, and pneumonic plague.  Naturally occurring plague is spread by flea-borne 
transmission and most commonly is exhibited in bubonic form.  This disease state is 
characterized by general malaise, fever, headache and the trademark buboes; necrotic, 
swollen lymph nodes from excessive bacterial proliferation.  Without an early diagnosis 
and antibiotic treatment there is a 60% fatality rate from bubonic plague, primarily from 
secondary sepsis and accompanying complications.  The bacteria grow to remarkable 
numbers, in a terminal patient up to 109 bacteria/ml can be reached in the bloodstream. 
In primary septicemic plague, which occurs 30% of the time from flea-borne 
transmission, buboes are absent making diagnosis difficult (4, 5).
The most lethal form of infection is pneumonic plague, with a nearly 100% 
fatality rate without treatment within 24 hours of symptom onset.  Primary pneumonic 
plague has a quick time of onset, as early as 24 hours following exposure.  Symptoms 
include fever and malaise, and coughing with difficulty breathing.  Death occurs from 
sepsis or respiratory failure.  Again, the infection is marked by an incredible amount of 
bacteria in the lungs (6, 3).
All three forms of plague have a noticeable absence or severely mitigated immune 
response in the early stages of infection.  The bacterium uses multiple methods in its 
biology to stealth past the host innate immune system.  This allows Y. pestis to grow to 
the extreme abundance seen in septic patients.  It is hypothesized that the bacterium 
utilizes this strategy for propagation; after growing to high numbers can effectively be 
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taken back into a flea vector through a blood meal (7).  Furthermore, the death of the 
human host forces the flea vector to seek other hosts, which propagates the bacterium (2).
Plague, the double-edged sword
Y. pestis is an ancient pathogen and has been used in warfare since antiquity.  One 
of the earliest documented examples of biological warfare involving Y. pestis was in 
1346, two years before the infamous Black Death epidemic in Europe (8).  Mongol 
Tartars were besieging the city of Kaffa, Crimea, which is in present day Ukraine.  The 
Tartars were being ravaged by an outbreak of plague and decided to launch their dead 
into the city by catapult.  Despite the primitive tactics, the strategy may have been 
successful and the inhabitants of the city were infected by plague as well.  Subsequently, 
the Crimeans fled towards various areas of Europe, which is speculated to have played a 
role in the start of the Black Death epidemic (8).
As recently as the 1980’s, the Soviet Union had an extensive biological weapons 
program with development of plague for use as an aerosol in long-range missiles (9). 
The offensive program has ended; however, there is potential for “rogue” scientists to aid 
in development of weapons to as many as 12 states suspected of biological weapon 
programs (8, 3).
Y. pestis is currently ranked as a Category A bioterrorism agent by the CDC.  The 
threat from an aerosolized weapon is disturbing given the acute nature of a pneumonic 
plague infection.  In addition, there is legitimate concern of bioengineered antibiotic 
resistance in the case of a terrorist attack using plague.  The narrow window for diagnosis 
and treatment of pneumonic plague would be exacerbated by the complications that an 
antibiotic-resistant strain would bring.  Because of the threat of bioterrorism, or the 
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possibility of biological warfare; research into Y. pestis biology for alternative methods of 
treatment and viable vaccine candidates is desirable.
Type Three Secretion System
The type III secretion system (T3SS) is an essential virulence factor of plague (10, 
11).  It is a syringe-like apparatus encoded by the ~70 kb plasmid CD1 (12, 13).  The 
T3SS delivers effector proteins vectorially into host cells, without leakage into 
extracellular space (14).  These effectors serve to decrease phagocytosis of the bacterium, 
increase intracellular survival in phagocytes, and dampen the immune response through 
decreased cytokine production (15).  The action of the T3SS is partially responsible for 
the delayed immune response seen in a Y. pestis infection.  Other gram-negative 
pathogens also encode these apparatuses, which have related functions in other pathogen-
host interactions (16).
T3SS effectors
There are multiple effectors to accomplish the T3SS-mediated effects.  Originally 
identified by centrifugation techniques, the effectors were termed Yersinia outer proteins, 
or in short, Yops (17).  Many Yops have specific chaperones that they interact with in the 
bacterial cytoplasm (18).  The exact function of the chaperones is unknown, although two 
hypotheses are storage of preformed effectors or possible prevention of folding before 
secretion (19, 20).  Little is known about events just prior to secretion, but a signal is 
believed to be sent upon eukaryotic cell contact.  An ATPase is known to play a role, 
termed YscN.  The ATPase provides energy for dislocation of chaperone from Yop, so 
the effector can fit into the secretion needle (15).  Once delivered into the host cell, they 
act differentially to exert their function.
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YopH
YopH is a potent tyrosine phosphatase that is important for the antiphagocytic 
function of the T3SS in plague (21).  YopH accomplishes this by interfering with actin 
rearrangements in the phagocyte, and by blocking formation of focal adhesion complexes 
(22).  YopH has also been shown to cause interference of cell signaling through its 
phosphatase activity, which disrupts cytokine production in phagocytes (23).  Outside of 
innate immunity, YopH can disrupt B-cell receptor expression and damper T-cell 
proliferation and cytokine production (24).  While interesting, the effect on B-cells might 
play a small role in vivo since it has been shown that macrophages, neutrophils, and 
dendritic cells are the preferred targets of Yersinia T3S activity (25).
YopE
YopE is a GTPase activating protein (GAP) (26).  After injection into a 
phagocyte, YopE induces GTP hydrolysis by Rac-1 and RhoA GTPases (27).  The GAP 
activity disrupts modification of the actin cytoskeleton, which contributes to the 
antiphagocytic property of Y. pestis (26, 27).  YopE has also been shown to reduce 
cytokine production through inhibition of caspase-1 in macrophages, preventing 
maturation of IL-1β and IL-18 cytokines (28).
YopT
YopT is a cysteine protease that synergistically acts with YopE and YopH to 
inhibit phagocytosis through disruption of the actin cytoskeleton (29).  YopT also targets 
Rho GTPases, through cleavage of a critical modification on the enzyme rendering it 
unable to interact with essential regulators (30, 23).
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YopJ
YopJ is another cysteine protease that induces macrophage apoptosis and disrupts 
the NF-kB pathway resulting in an inhibition of cytokine release (31, 32).  YopJ plays a 
large role in the enteropathogenic Yersinia, but has been shown to only play a minor role 
in Y. pestis pathogenesis (13).
YopM
YopM is an essential effector of Y. pestis virulence, but has remained somewhat 
mysterious in its specific function (33, 15).  YopM is known to travel to the nucleus of 
eukaryotic cells (34).  A YopM mutant has a 100,000 fold increase in LD50 compared to 
WT Y. pestis, in a mouse model (35).  This could possibly be from a systemic depletion 
of NK cells, through disruption of IL-15R on NK cells, and by lowering IL-15 cytokine 
production in macrophages (35).  Also, recombinant YopM reduced cytokine release in a 
LPS-induced macrophage model (36).  Taken together, YopM is another effector 
performing the common role of dampening the innate immune response in the host by 
destroying its ability to communicate distress through cytokine release.
LcrV
While not actively secreted into host cells by the T3SS, LcrV is included here for 
its role as a soluble effector in Y. pestis pathogenesis.    LcrV is involved in regulation of 
the T3SS, as well as being a part of the translocon structure at the tip of the needle 
apparatus.  The protein is a structural component, but is also known for its 
immunosuppressive properties making it an unusual virulence factor (13).  Mice 
immunized with LcrV showed a systemic downregulation of IFN-γ and TNF-α through 
action of IL-10 by LcrV binding to TLR-2 (37).  This was further proven by using an IL-
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10 KO mouse model, where after LcrV administration, higher inflammatory cytokines 
were elicited.  This higher cytokine level was accompanied with an increase in resistance 
to Yersinia challenge.  The immunosuppressive role of LcrV was proposed to be a “long-
range” function to accompany the cell-directed action of the T3SS (38, 13).
The immunosuppressive effects of LcrV are actively contested however.  The 
resistance to Yersinia challenge upon further investigation was shown to be specific to 
strains of mice used (39).  In addition, a study from different authors showed that the 
immunosuppressive effect is largely dependent upon high molecular-weight multimers of 
the protein (40).   LcrV does multimerize at the tip of the needle, but in the range of 3 to 
5 oligomers in Yersinia enterocolitica (41).  The higher molecular-weight species of 
protein that are responsible for the immunosuppressive effect are seen as artificial to 
over-expression by the authors and not physiologically significant (40).
T3SS structure
The T3SS structure has three domains; a basal body, needle and translocon at the 
tip of the apparatus.  The basal body consists of ten proteins that share significant 
homology with flagellar basal bodies.  In fact, the T3SS is essentially a needle on top of 
the conserved flagellar basal structure, rather than a hook and filament.  This has lead to 
the speculation of flagella being the evolutionary ancestor to the T3SS, although the point 
remains controversial (41).  As shown in Figure 1, the basal body is composed of several 
different proteins that span the inner and outer membranes of the bacterium.  The exact 
structure of the cytosolic face is unknown, but YscN putatively sits at the base to fulfill 
its function as an ATPase for the system.  HrcN, the ATPase from Pseudomonas 
syringae is known to associate with the inner membrane.  The cryo-electron structure of 
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HrcN demonstrated a pore in the middle of the protein.  From this structure, the authors 
concluded the ATPase must associate continuously with the base of the apparatus. 
Substrates of the T3SS would pass through the ATPase, which provides energy for 
secretion and dissociation of the associated chaperones (42).
YscJ oligomerizes into a ring structure located in the inner membrane of the 
bacterium (43).  YscD connects the inner membrane ring to the N-terminus of YscC, 
which spans the periplasmic space.  The C-terminus of YscC is located in the outer 
membrane where it is also in a ring shape.  YscC is an oligomer with 12-15 monomers 
forming its structure in the outer membrane (44).  The continuous association of YscJ, 
YscD, and YscC forms a channel that passes through the bacterium’s membranes.
The needle portion of the apparatus sits on top of the basal body structure.  The 
needle is composed of approximately 150 subunits of YscF (45, 46).  The rod protein 
YscI passes through the basal body, forming a scaffold on the interior of the basal body, 
necessary for stability and possibly to aid polymerization of the YscF subunits (47). 
Polymerization of YscF happens spontaneously, after secretion through the basal body 
using the T3S machinery (48).  The length of the needle is controlled by YscP, which 
functions as a “molecular ruler” to ensure the proper length of the needle substructure 
(49).
The translocon is composed of YopB, YopD, and LcrV; these proteins serve the 
role of inserting themselves through the host membrane so that a pore is formed to 
deliver Yops into the cell (50).  LcrV sits at the tip of the needle until eukaryotic cell 
contact, when YopB and YopD are recruited (51).  These hydrophobic proteins localize 
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distally to LcrV and form pores in the eukaryotic cell membrane, enabling translocation 
of effector proteins (50, 52).
Conservation of structure
There is a great deal of homology retained between structural elements of the 
T3SS among species of bacteria.  The structural proteins of the T3SS are retained in 
genetic blocks within their bacterial constituents.  This gives evidence that the T3SS was 
passed through horizontal gene transfer (53).
The wide-range of strategies employed by bacteria using the system is reflected in 
the diversity of their effector proteins.  While some motifs are retained, effector proteins 
are variable in their structure to execute their functions (54).
Homologs of needle proteins used in this manuscript are displayed in Figure 1. 
The gram-negative pathogens Salmonella enterica Sv. Typhimurium, and Shigella  
flexneri are in the Enterobacteriacae family and cause gastroenteritis in humans.  Vibro 
parahaemolyticus also causes gastroenteritis and is in the clade of γ-proteobacteria with 
the other bacteria listed in Figure 1.  Of note, the T3SS is essential to virulence in these 
pathogens similar to Y. pestis (55, 56, 57).
Pathogen-associated molecular patterns
Non-specific defenses are present in all potential hosts for pathogenic bacteria. 
The innate immune system is almost as ancient as the bacteria themselves, and evolved 
simultaneously with the pathogens.  Consequently, invariant microbial-specific molecular 
organizations are recognized by the innate immune system and referred to as pathogen-
associated molecular patterns (58, 59). 
Bacterial PAMP’s identified have included molecules such as lipoprotein,
9
Bacterial species Needle protein homolog
Yersinia pestis YscF
Salmonella enterica SPI-1 PrgI
Salmonella enterica SPI-2 SsaG
Shigella flexneri MxiH
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Figure 1.  T3SS apparatus and needle protein homologs.  Graphic reprinted from Structure, 19, Izore, 
T, et al. Biogenesis, regulation, and targeting of the type III secretion system, 603-612, 2011, with 
permission from Elsevier.
lipopolysacchride, peptidoglycan, flagellin, and unmethylated CpG-DNA (60-64).  These 
are prototypical examples of PAMP’s because of their unvarying nature and absolute 
necessity to the bacterium’s survival.
Pathogen recognition receptors
The host recognizes these PAMP’s through germline-encoded receptors termed 
pathogen recognition receptors (PRR) (65).  These receptors are located on immune 
effector cells such as macrophages, neutrophils, dendritic cells, and mast cells.  After 
recognition of a PAMP through binding to a PRR, the innate immune system activates; 
alarming and directing the adaptive arm of immunity through cytokine production and 
upregulation of co-stimulatory molecules.  
Toll-like receptors
  The Toll-like receptors (TLR) are a family of PRR receptors that are considered 
the predominant sensors of innate recognition (66).  The family was originally identified 
in Drosophila, as a receptor named responsible for dorsal-ventral orientation.  Later, the 
human homologs were discovered and shown to bind to various PAMP’s (58).  The 
family of receptors is characterized by an extracellular leucine-rich region and a 
cytoplasmic Toll/interleukin-1 receptor (TIR) domain (64).  Humans have 10 different 
TLR’s that form homodimers of themselves with the exception of TLR2 that forms 
heterodimers with other TLR’s giving the TLR2 complex broader specificity for agonists.
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The binding of a TLR agonist to the receptor starts a signaling cascade in its 
effector cell.  An adaptor protein, such as MyD88, is recruited to the TIR domain, 
subsequently MAP kinase cascades result in NF-kB activation.   NF-kB is a transcription 
factor that upregulates proinflammatory genes ultimately leading to activation of the 
immune system.
YscF as a PAMP
Previous work in our lab has shown that N-terminally truncated YscF (trYscF) 
was pro-inflammatory in a Y. pestis murine infection model (1).  The needle protein was 
inoculated into C57BL/6N mice as described in Matson, 2005 (67).  Serum collected 14 
days after inoculation from mice vaccinated with trYscF, showed a significant increase in 
pro-inflammatory cytokines compared to the full-length YscF.  This in vivo result was 
confirmed in vitro with THP-1 cells, a human monocyte cell line.  24 hours after 
exposure to trYscF, the monocytes released significantly more TNF-α compared to the 
THP-1 cells exposed to full-length YscF (1).  This demonstrated an ability of YscF and 
trYscF to induce pro-inflammatory cytokine release in two different experimental models 
(1).
The results in this thesis explore treatment with other needle homologs of YscF 
with in vitro macrophage tissue culture, using primarily TNF-α as a marker of activation. 
Full-length versions of the proteins will be tested alongside an equivalent truncation of 
the N-terminus compared to YscF.  Needle homologs from S. enterica Sv. Typhimurium 
Salmonella pathogenicity island-1 (SPI-1) and SPI-2 are used, PrgI and SsaG 
respectively.  S. flexneri needle homolog MxiH is also tested.  The human monocyte 
THP-1 tissue culture is used as well as primary macrophages from C57BL/6N mice to 
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measure cytokine response to the bacterial needle protein.  Our hypothesis is that 
truncated homolog needle proteins will produce an inflammatory response in macrophage 






THP-1 monocytes were maintained in an atmosphere of 5% CO2 at 37° C. 
Medium was RPMI-1640 complete (Mediatech, Manassas, VA); 10% v/v fetal bovine 
serum (Atlanta Biological Laboratories; Lawrenceville, GA), 2mM glutamine 
(Mediatech), 0.05 µM β-mercaptoethanol (Fisher BioReagents, Fairlawn, NJ), 2mM 
Cellgro® antibiotic-antimycotic solution (Mediatech).  The monocytes were propagated 
according to ATCC guidelines; passaging was accomplished at 8x105 to 1x106 cells/ml, 
every 2-3 days to a density of 2x105 cells/ml.  Cell viability was assessed by trypan blue 
exclusion staining.  PMA-treated monocytes were exposed to a concentration of 160nM 
PMA for a 24 hour time period.  They were verified to have differentiated into an 
adherent cell type, with greater than 95% of the monocytes adhering to the culture flask. 
The treated THP-1 cells were washed once with complete medium before protein 
induction.
B6 Peritoneal Macrophages
Peritoneal macrophages from C57BL/6N mice were obtained from Dr. Nathaniel 
Lambert, University of North Dakota.  They were maintained in RPMI-1640 complete 
(Mediatech) for 48 hours in 24-well plates at a density of 8x105 cells/ml.  Before 
experimentation, they were washed with RPMI once to remove non-adherent cells.  Fresh 




Plasmids used in this thesis were constructed using Champion™ TOPO 
expression kits (Invitrogen, Carlsbad, CA).  Primers for gene amplification were made by 
Eurofins MWG Operon, Inc (Huntsville, AL).  Primers used for cloning were as follows: 
WT PrgI forward 5’- CAC CAT GGC AAC ACC TTG GTC-3’, PrgI reverse 5’- TTA 
ACG GAA GTT CTG AAT AAT GGC AG-3’, WT SsaG forward 5’-CAC CAT GGA 
TAT TGC ACA ATT AGT GGA TAG CTC TCC-3’, SsaG reverse 5’-TCA GAT TTT 
AGC AAT GAT TCC ACT AAG CAT ATC C-3’, Truncated SsaG forward 5’-CAC 
CCT CTC CCA CAT GGC GCA C-3’.  Template DNA for amplification was generated 
using DNeasy kit (Qiagen; Valencia, CA); the manufacturer’s instructions were followed. 
PCR was conducted using PFU Turbo® polymerase (Agilent Technologies, Santa Clara, 
CA).  Amplified DNA was then placed in pET200 using the Champion™ TOPO 
expression kit, manufacturer’s instructions were followed.  All of the gene constructs 
were sequence verified by Eurofins MWG Operon.  Vectors were stored in TOP10 E. coli 
by chemical transformation. WT and truncated MxiH and truncated PrgI encoding 
plasmids are a kind gift from Dr. William Picking, Oklahoma State University.  
Recombinant Protein Expression
Protein expression
Plasmids for protein expression were purified from TOP10 E. coli by Qiaprep 
Miniprep kit (Qiagen).  Purified plasmid DNA was then transformed into the expression 
host, BL21 (DE3) Star™ (Invitrogen, Carlsbad, CA).  Protein expression was conducted 
as described by Studier, 2005 (68). Auto-induction was found to result in optimal protein 
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expression at 6 hours of growth.  Cells were harvested by centrifugation and resuspended 
in wash buffer.  Wash buffer consisted of 50 mM Na3PO4, 300 mM NaCl, and 10% w/v 
glycerol (Fisher Chemical; Fairlawn, NJ).  The cells were passaged two to four times 
through a French cell press at a pressure of 18,000 lb/in2 until an opalescent product was 
obtained.  The cell lysate was spun at 20,000 x g for 10 min to clarify the soluble protein. 
Protein purification was conducted using Talon resin (Clontech; Mountain View, CA), 
manufacturer’s instructions were followed.  The purified protein was extensively 
dialyzed against a solution of PBS and 20% w/v glycerol.
Concentration and Quantification of protein
The purified protein product was concentrated using an Amicon Ultra-15 unit 
(Millipore; Billerica, MA).  Protein was quantified using a Pierce BCA protein assay kit 
(Thermo Scientific; Rockford, IL), manufacturer’s instructions were followed.  SDS-
PAGE was conducted on a 15% gel as described in (69).  Protein was suspended 1:1 with 
2x SDS sample buffer and boiled for 5 minutes before loading on gel.  Protein was 
aliquoted and stored at -20°C before experimentation.
Cytokine Induction Experiments
Induction of THP-1 cells was conducted after seeding the cells into 24-well tissue 
culture plates at a density of 8x105 cells/ml in induction medium, RPMI-1640 without 
FBS.  The cells were acclimated to the wells for 2-8 h before addition of needle protein. 
Protein was applied at a concentration of 1µg/ml or 105 nM as noted per experiment. 
LPS positive control was applied at a concentration of 1µg/ml.   THP-1 cells were 
incubated with the respective proteins for 5 or 24 hrs at 37°C in a 5% CO2 environment. 
Cells were then pelleted by centrifugation, 250 x g for 10 min at 4°C.  Culture 
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supernatants were collected for cytokine analysis; care was taken to not pipette any 
cellular particulates.
Cytokine analysis
Cytokine concentration was measured by ELISA.  Human TNF-α was measured 
by Quantikine® Colormetric Sandwich ELISA (R&D Systems; Minneapolis, MN). 
Mouse TNF-α, and human cytokines IL-4, IL-6, IL-8, IL-15, and IL-17A were measured 
by Ready-Set-Go!® Sandwich ELISA (Ebioscience, San Diego, CA).  Four-parameter 
logistic regression was used to create standard curves for quantification of cytokine 
concentrations.  Statistical analysis of the data was performed by Prism Graphpad Sigma 
v5.0d (LaJolla, CA).  One-way ANOVA was used with Tukey’s post-hoc test.  p values 




Previous work showed that the Y. pestis T3S needle protein YscF and an N-
terminally truncated variant of YscF trigger release of pro-inflammatory mediators from 
cells (1).  This ability was demonstrated with cultured cells in vitro and in vivo in a 
mouse model (1).  To expand on this observation, homologs of YscF with similar N-
terminal modifications were tested to further understand this phenomenon.  Additional 
needle proteins tested were S. flexneri MxiH, S. enterica Sv. Typhimurium SPI-1 PrgI, 
and SPI-2 SsaG.  The hypothesis is that homolog needle proteins will be recognized by 
tissue macrophages as pathogenic and elicit an inflammatory response from the cells 
similar to the YscF needle protein.
Figure 2A shows a CLUSTAL V alignment of the four proteins, with sequence 
conservation labeled in yellow.  The CLUSTAL V alignment algorithm was used because 
it is well suited to analyze terminal variations like in the case of the highly variable N-
termini of these T3SS needle proteins (96).  A cursory look at the needle proteins shows 
that the middle and C-terminal portions of the proteins are relatively conserved in 
contrast to the highly variable N-terminus.  In particular, certain residues are identical in 
all four proteins, these residues are likely important to form the final needle structure. 
Importantly, these needle proteins form multimers in vivo that have been shown to be 
abrogated by cleavage of five amino acids on the C-termini of MxiH, PrgI, and BsaL (70, 
71).  Since needle proteins are so strongly conserved in that region, it is inferred that the 
region is critical for polymerization in other needle proteins as well (72, 73).
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A truncation of each respective protein that would correspond to the YscF 1-22 
truncation was found after alignment with YscF.  This yielded a deletion of residues 1-18 
from MxiH, 1-17 of PrgI, and 1-9 of SsaG.  Overexpression of these proteins was 
conducted as previously described (68), using a T7-based system.  Purification was 
conducted on a cobalt resin column, utilizing a His6-tag on the N-termini of the 
recombinant protein.  In addition, there is an 8 amino acid epitope marker encoded by the 
vector for identification with antibodies directly subsequent to the His6-tag and before the 
protein sequence.  The proteins were kept in a 20% w/v glycerol solution to decrease 
non-specific protein interactions (74).  WT and truncated versions of each protein were 
overexpressed as described in methods then resolved using SDS-PAGE on a 15% gel for 
visualization (Fig. 2B).  The needle proteins have an approximate weight of 9 kDa, and 
the resolved gel yielded several discrete bands of protein. This ladder effect was expected 
as a normal property of the naturally polymerizing protein, and has acted in this way in 
our hands as well as others (67, 72). The addition of glycerol was successful in limiting 
non-specific aggregation of protein after a freeze-thaw cycle, demonstrated by lack of 
visible protein precipitation in the solutions.
To test the potential PAMP activity of these proteins, we used tissue culture 
models that are known to express receptors capable of detecting these pathogenic motifs. 
First, primary peritoneal mouse macrophage cells obtained by peritoneal lavage of B6 
WT mice were used.  TNF-α was used as a marker of macrophage activation, which is 
extensively characterized as an important inflammatory cytokine produced primarily by 
macrophages.  TNF-α is important due to its role in systemic inflammation, increasing 




Figure 2.  Production of homolog proteins.  Panel A depicts alignment according to CLUSTAL V 
method using Megalign software.  Yellow coloring indicates identical amino acids in at least two 
homolog proteins.  Panel B shows results of protein purification; 5 µl samples of protein were run on a 
15% SDS gel after being solubilized in 2x SDS sample buffer and boiled for 2 minutes.  Gel was fixed 
and silver stained for visualization.
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disorders (75). TNF-α is maximally expressed at 4-5 hours after exposure to a PRR 
agonist (76).  Since TNF-α was the primary marker of activation, we used a 5 h time 
point throughout these experiments to maximize the level of TNF-α release providing 
clarification of any differences between treatments.
Macrophages were exposed to the needle proteins at a concentration of 105 nM, 
the equivalent concentration of 1 µg/ml of YscF, the concentration used in prior 
experimentation with YscF (1).  The supernatants were analyzed by ELISA and data 
normalized according to LPS activation.  As shown in Fig. 3, truncated YscF was used as 
a positive control and elicited TNF-α release from the murine macrophages.  PBS with 
20% glycerol w/v (assay diluent) served as a negative control for the experiments.  WT 
PrgI elicited a small amount of TNF-α release, and was statistically lower than the TNF-α 
response from the N-terminally truncated PrgI.  The elicited response to WT SsaG was 
not statistically different from TNF-α release stimulated by truncated SsaG in this 
experiment.  Both variants of SsaG elicited TNF-α release from the macrophages, in 
contrast to the other needle proteins tested.  The response elicited by WT and truncated 
MxiH was persistently variable and made conclusions about MxiH’s ability to stimulate 
TNF-α release difficult in this experiment.
Murine macrophages have been shown to express TLR’s differently than human 
macrophages (77).  Specifically, TLR5 is not expressed by murine bone marrow-derived 
macrophages, or peritoneal macrophages (77).  This is in contrast to human macrophages 
and dendritic cells which do produce TLR5 (78).  The induction experiment shown in 
appendix A (Fig. 7) shows the response of murine BM-derived macrophages.  These 
macrophages showed inflammatory responses to the needle proteins.  This data taken 
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together with the results in figure 3 demonstrate independence from TLR5 signaling as a 
potential mechanism of activation for the inflammatory needle proteins.
Figure 3.  Protein induction in B6 peritoneal macrophages.  Peritoneal macrophages were seeded at a 
concentration of 8 x 105 cells/ml in RPMI-1640.  Protein was applied at a concentration of 105 nM 
and incubated for 5 hours before supernatant was collected for cytokine measurement.  Mouse TNF-α 
ELISA was used to measure cytokine release, and data was normalized compared to LPS control.  % 
activation is defined by TNF-α release in response to treatment.  Graph represents the results of 2 
experiments with an n=6. Error bars are S.E.M.  Statistical significance determined by Tukey’s post-
test.  *, p <0.05.
The monocyte cell line, THP-1, was next used to study the effect of these needle 
proteins in a human cell line model.  Identical methodology was used in experimentation 
as with the murine cell line.  Fig. 4A shows the results of TNF-α release from the 
monocytes, normalized to LPS activation.  Again, truncated PrgI was significantly higher 
in activating monocytes compared to its WT counterpart, with the truncated protein 
producing approximately 50% of the LPS activation.  In THP-1 monocytes, there was a 
statistical difference between the responses to WT and truncated SsaG, and it should be 
noted that the WT SsaG treatment produced more of a TNF-α response than the other WT 
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proteins tested.  MxiH data is presented in appendix A  (Fig.8).  Again, the response was 
variable, however statistically the WT and truncated MxiH produced a non-significant 
difference from each other.  TNF-α cytokine release was also measured at 24 hours (Fig. 
9).  The quantity of TNF-α was globally diminished at the 24 hour timepont, however 
trends between WT and truncated protein were comparable to the 5 hour time point. 
Additionally, Vibrio parahaemolyticus needle protein VYscF elicited an inflammatory 
response of 1,700 pg/ml TNF-α in THP-1 monocytes in one experiment after N-terminal 
truncation.
Figure 4B shows protein induction in PMA-treated THP-1 cells that have been 
differentiated into a macrophage cell type.  TNF-α induction trends were retained 
between WT and truncated proteins (Fig. 4A).  The PMA-treatment made the THP-1 
cells more responsive to the proteins, with the truncated protein phenotype changing from 
50% LPS activation to 75% of the LPS activation (Fig. 4). Therefore, in both murine and 
human macrophage cell types, truncated PrgI reacts in a similar way to truncated YscF in 
eliciting a response from macrophages.  WT SsaG produces a response that is little 
different from the amount of TNF-α release elicited by truncated SsaG.
To further understand how THP-1 monocytes respond to the needle proteins, we 
next looked at IL-8 release.  IL-8 is an important chemokine produced by macrophages. 
IL-8’s main function is attraction and activation of neutrophils at the site of infection 
(79).  Figure 5 shows that truncated YscF, PrgI, and SsaG treatments resulted in similar 





Figure 4.  TNF-α release from protein induction in THP-1 culture.  Panel A shows the induction 
experiment in THP-1 non-activated monocyte culture, at a concentration of 8 x 105 cells/ml. Panel B is 
activated THP-1 cells, accomplished through 24 hour incubation with PMA causing the cells to 
become adherent before application of protein.  Protein is applied at 105 nM and incubated for 5 
hours, before supernatant was collected for cytokine measurement.  % activation is defined by TNF-α 
release in response to treatment, normalized to the response to LPS.  Panel A represents 3 independent 
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experiments with n=9.  Panel B represents 1 experiment, n=3. Error bars are S.E.M.  Statistical 
significance determined by Tukey’s post-test.  *, p <0.05.  
WT PrgI.  SsaG is significantly different from the truncated SsaG treatment, while still 
producing a response.  These results carried the trends seen in the TNF-α cytokine data. 
Other cytokines were measured to fully characterize the response produced by the 
macrophages.  The cytokines chosen represent different strategies of the immune system 
for overcoming infection.  IL-17A is primarily produced by Th17 T cells and is 
representative of a neutrophil-driven response from the immune system (80).
Figure 5.  IL-8 release from protein induction in THP-1 culture.  Protein induction experiment 
showing IL-8 cytokine release in THP-1 monocyte culture.  Protein is applied at 105 nM and 
incubated for 5 hours, before supernatant was collected for cytokine measurement. Graph represents 3 
independent experiments, n=9.  Error bars are S.E.M.  Statistical significance determined by Tukey’s 
post-test.  *, p <0.05.  
IL-15 promotes NK cell and CD8+ T cell proliferation and differentiation (81). 
IL-6 is another important cytokine for systemic inflammation, long known for its role in 
the acute phase response and as a lymphocyte stimulator (82).   IL-4 acts on humoral 
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immunity by increasing B-cell proliferation and by reinforcing a Th2 response from 
CD4+ T cells (83).  As shown in figure 6, there was no significant difference between 
any of the treatments for IL-17A with the negative control, with all treatments producing 
a small amount of IL-17A but WT YscF.  IL-17A is not a typical cytokine expressed by 
monocytes, and the results seen may have been a baseline level of expression.  IL-15 and 
IL-6 had similar trends, with treatments not being significantly different from each other 
or controls.  IL-4 did not have a response, which might have been under the sensitivity of 
the ELISA.  For the cytokines tested in figure 6, additional investigation is needed at a 
later timepoint than 5 hrs.  While TNF-α is maximally expressed at this timepoint, other 
cytokines such as the ones measured in figure 6 are expressed at later timepoints such as 
24 hrs.
These results demonstrate that induction of cytokines by YscF, truncated YscF, 
and other protein homologs is conserved across species of bacteria, indicating that the 
protein is recognized as a PAMP by the innate immune system.  Further, the variable N-
terminus that is present on these needle proteins appeares to interfere with this 
recognition of the PAMP by macrophages in both mouse and human tissue culture 
models.
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Figure 6.  Various cytokines released from THP-1 protein induction.  THP-1 cells were seeded at a 
concentration of 8 x 105  cells/ml.  The monocytes were induced with 105 nM of respective protein. 
Supernatant was collected at 5 hours and measured for appropriate cytokine by ELISA.  IL-6, IL-17A, 
IL-15, and IL-4, are the results of one experiment with an n = 3.  Error bars are S.E.M.  Statistical 




YscF is a PAMP
Y. pestis is a gram-negative pathogen responsible for multiple pandemics in 
human history (2).  The action of Y. pestis’ T3SS is essential for virulence (13), and the 
effectors secreted from this apparatus allow the bacterium to avoid phagocytosis and aid 
survival in macrophages if phagocytosis is accomplished (14).  Use of a T3SS by Y.  
pestis is not unique to the pathogen and is expressed in many other gram-negative 
pathogens, from the fellow Enterobacteriaceae S. flexneri, to plant pathogens such as 
Pseudomonas syringae (51).  The structure of the T3S systems is highly conserved and 
exposed portions of the apparatus, such as the needle, have potential to be recognized by 
the host as a pathogen-associated molecular pattern and be inflammatory if detected.
This thesis demonstrated that modified T3SS needle proteins are capable of 
eliciting a strong inflammatory response from macrophage tissue culture.  This was 
demonstrated with N-terminally truncated YscF, PrgI, and SsaG; which belong to Y.  
pestis, S. enterica Sv. Typhimurium SPI-1 and SPI-2 respectively.  We chose the needle 
protein SsaG for experimentation because it lacks the variable N-terminus that most 
T3SS needle proteins possess, essentially making SsaG a natural truncation. 
Interestingly, the wildtype SsaG protein was also inflammatory, equal or similar to the 
truncated versions of the protein, which strongly supports the notion that the observed 
inflammatory effect is a relevant biological response.  We saw this effect in both human 
and mouse macrophages, indicating the PRR responsible for detection of the needle 
protein is expressed in both organisms.
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An exception to the trends displayed by PrgI, SsaG, and YscF was the S. flexneri 
homolog MxiH.  MxiH’s elicited response in macrophages was variable leading to 
difficulties in interpretation of the data.  The data with THP-1 monocytes, however, 
showed a repeatable non-significant difference between WT and truncated MxiH 
proteins, with neither producing an inflammatory response.   If the truncation to MxiH 
does not produce a response in macrophages, this could provide valuable insight into the 
mechanism for producing inflammatory effects in response to the other homologs by 
analyzing the limited differences in structure between MxiH and other needle proteins.
The five hour timepoint used in the experimentation was selected for maximal 
expression of TNF-α in macrophages.  It should be noted, however, that 5 hours post-
induction is of limited utility for other important cytokines: IL-17, IL-15, IL-6, and IL-4, 
as evidenced by the minimal expression.  A later timepoint, such as 24 hours, would be 
more optimal for study of those cytokines, if they are induced by needle proteins.
Truncated YscF as a vaccine
The data in this thesis agrees with prior work done in our laboratory on YscF and 
its pro-inflammatory properties.  YscF has been shown to be protective in a mouse model 
of Y. pestis infection (67).  In efforts to further study YscF as a potential vaccine 
candidate, the protein was epitope mapped with antiserum from mice exposed to the WT 
protein (1).  Two areas were found to have antibodies generated against them; a major 
epitope on the N-terminus at roughly resides 8-15, and a minor epitope in the middle of 
the protein next to the turn between the two α-helices that would be solvent-accessible, a 
good antigen candidate (1).  The N-terminus, while the major epitope, is relatively non-
accessible after polymerization of the needle; it folds back in on the middle and C-
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terminal portions and is on the interior of the needle structure, which limits its exposure 
to the solvent (84).  In an effort to push the host antibody response to the more accessible 
minor epitope at the helix-turn-helix, the N-terminal 22 amino acids were truncated from 
YscF, which removed the major epitope.  Subsequently, immunization of mice was 
conducted and followed by exposure to Y. pestis.  Interestingly, average time to death 
was lower with the mice immunized with truncated YscF, compared to WT YscF 
immunized mice (1).  Analysis of the cytokines in the collected serum indicated that the 
mice with the truncated YscF immunization had much higher quantities of pro-
inflammatory cytokines after Y. pestis exposure compared to the WT YscF immunized 
mice (1).  This unexpected result was followed up through in vitro experimentation with 
THP-1 human monocytes, which repeated the observation by seeing a significant pro-
inflammatory response with the truncated YscF protein, and relatively little response 
from the WT protein.
Function of the variable N-terminus?
We wanted to expand on the previous work (1), in this thesis by showing that 
other needle proteins are also recognized as PAMP’s by the host immune system. 
PAMP’s can be predicted based upon three properties of being: essential to the pathogen, 
conserved in structure across species of bacteria, and distinctly “non-self” in terms of the 
host defense mechanisms (65).  If attempting to predict a PAMP, this makes the T3SS 
needle a good candidate as it is readily exposed to the host, the solvent-accessible portion 
of the needle is strongly conserved between pathogens, it is essential to the virulence of 
the pathogens studied in this thesis, and there are no eukaryotic homologs present in the 
host.  
30
The data presented in the thesis supports the hypothesis that the needle protein 
functions similarly across species of bacteria, and reinforces the idea that the 
inflammatory effect seen after N-terminal truncation in YscF is not unique or artifactual. 
PrgI is the SPI-1 homologue in S. enterica Sv. Typhimurium, which acts in a way that is 
similar to the T3SS of Y. pestis in that it is expressed in the extracellular environment of 
the host.  Structurally, the two T3SS’s share homology, but the comparison ends there. 
Y. pestis expresses effectors that actively avoid phagocytosis and has an overarching 
strategy of subterfuge with the innate immune system (3).  The SPI-1 system however, 
actively induces inflammation to obtain access through the intestinal epithelium by 
injecting its effectors that induce inflammation (85).  After induced phagocytosis, the 
SPI-2 system takes precedence during Salmonella infection.  SPI-2 functions control 
biogenesis of the intracellular Salmonella-containing vacuole (SCV) that is crucial for 
systemic survival of the pathogen (56).  The SPI-2 T3SS is expressed in its intracellular 
niche and is exposed to a very different environment in the vacuole than the extracellular 
environment of SPI-1 (86).  As shown before in figure 2A, SsaG is missing the majority 
of the highly non-conserved N-terminus that most T3SS needle proteins have.  
This raises the question of the function performed by the N-terminus of the needle 
proteins.  The fact that the N-terminus of needle proteins is highly variable in 
composition and length, even to the point of being absent suggests that it is not critical to 
the central function of the needle, which is to provide a conduit for effectors from 
bacterium to eukaryote host.  One could make the supposition that the interior of the 
needle needs to be non-interactive with species-specific effectors to prevent a blockage of 
the small space on the interior of the needle.  Between species of bacteria, the effectors of 
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the T3SS are very variable compared to the actual structure, so it would be logical for the 
interior of the needle to have the most variation in the needle structure.  This potential 
function of the N-terminus is countered by evidence showing that effectors from other 
species of bacteria are able to be secreted in different systems; for example, Chlamydia 
effectors are able to be secreted in the Yersinia or Salmonella T3SS (87, 88).  With this 
evidence in mind, the N-terminus is likely not important in effector secretion and is 
present for another function.
The data in this thesis shows that removal of the N-terminus of the needle protein 
causes YscF and PrgI to go from relatively innocuous, to causing a significant release of 
TNF-α and IL-8 from macrophages.  This leads to the reasoning that the N-terminus 
either obscures the PAMP-site that a receptor is able to recognize, or is causing a change 
in conformation in the needle or needle proteins that identifies the needle as a pathogen 
for the respective PRR.
The choice between these two hypotheses is contingent on a question, is the 
needle protein stimulating its PRR as a monomer/dimer or in its polymerized needle 
structure?  Unfortunately, our data so far does not give an answer to this question, as the 
protein purification yields bands of monomeric protein to high molecular-weight 
multimers.  If the protein is stimulating the receptor as a monomer, one could easily see 
how bacterial evolution of an N-terminus to physically obscure the receptor’s recognition 
could happen.  This hypothesis assumes that addition of the N-terminus is an 
evolutionary recent event, and could account for the variability in the region seen across 
species of bacteria.  Furthermore, even in species of bacteria that actively induce 
inflammation, such as the strategy of Salmonella with its SPI-1 T3SS, one could argue 
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that the inflammation process is able to be regulated by the bacterium.  Whereas an 
inflammatory needle could be a constitutively active mechanism.  
Alternatively, it is possible that the higher molecular weight species of protein 
from overexpression are activating a PRR after polymerization into a needle structure.  In 
the context of the final needle structure, the idea of the N-termini of these proteins 
“hiding”, as in disallowing spatial access, a PAMP in the needle seems unlikely as the N-
terminus is predicted to line the interior of the needle (84).  Due to the invariant nature of 
pathogen recognition receptors, it seems peculiar that creating an artificial change to the 
interior of the needle structure would suddenly activate one of these germline-encoded 
receptors.  However, if the needle is exposed to the host in more than one conformation 
of its structure, the truncation to the protein could have forced the needle into a 
conformation that is recognized by the host as pathogenic, while the in vitro wildtype 
protein is in a constitutively non-inflammatory form.  As a counterargument to the 
truncated needle protein possibly replicating a conformation that is seen in vivo, it should 
be noted that the truncated YscF does not complement a mutant’s phenotype when 
expressed on a plasmid in Yersinia pestis (G.V. Plano, personal communication).
The idea that the T3SS needle might have more than one conformation is not 
novel.  The closest crystal structure we presently have for YscF is the MxiH structure, 
which the authors reported an “A” and “B” form in their study (89, 84).  The difference 
in conformations was largely in a different angle in the region we identified as a minor 
epitope, which interestingly corresponds to the area that YscF could interact with the 
needle tip protein, LcrV.  Furthermore, it is known that the T3SS does not secrete non-
specifically into the environment, but rather translocates exclusively into host cells.  The 
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signaling mechanism for host-cell contact is currently unknown.  However, since there 
are multiple needles on a bacterium’s surface, in the range of 10’s to 100’s depending on 
the species (45), the control of translocation almost has to be specific to each needle 
structure.  There are no auxiliary structures connecting the host and bacterium on each 
individual needle, so it is reasonable to assume the signal of host-cell contact must be 
conveyed through the needle itself.  
The possibility of the N-terminus being involved in changing the conformation of 
the needle structure, and consequently sending a secretion signal is potentially held back 
by the absence of this region on SsaG, since the SPI-2 system does not constitutively 
secrete effectors.  However, a recent study shows that the SPI-2 system expression and 
signal for secretion could be controlled in a different manner from most T3SS’s, by the 
very distinct change of pH from the host lumen to the Salmonella-containing vacuole 
(90).  This strong signal of pH for appropriate timing of SPI-2 secretion is a mechanism 
that most bacteria must generate on their own in the absence of a distinct environmental 
signal.  If the N-terminus’ function is to change the conformation of the needle to convey 
the secretion signal, the functionality of this region in hiding the pathogenicity of the 
needle would be secondary or possibly even coincidental.  This topic holds great interest 
for general T3SS biology, and further investigation on the function of the N-terminus of 
the T3SS needle bears merit.
Which PRR is stimulated?
The pathogen recognition receptor (PRR) that is activating in response to 
truncated YscF, PrgI, and SsaG is currently unknown.  PRR is a very broad description of 
multiple classes of receptors that are able to recognize pathogenic proteins, lipoproteins, 
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lipids, and nucleic acids (66).  A good candidate in future studies on this phenomenon 
would be the TLR class of PRR’s, and in particular the externally expressed TLR’s, 
TLR1/2, TLR2, TLR4, TLR5, and TLR2/6.  TLR5 was shown in our data to not be a 
major player in the inflammatory response, mouse bone-marrow and peritoneal 
macrophages have been shown to produce little or no TLR5 (77), and we still observed a 
strong inflammatory response in those macrophages.  However, TLR2 has been shown to 
recognize bacterial protein (91), and has shown the broadest specificity to PAMP’s 
through its heterodimer structures.  One direction to study the mechanism of activation 
would be to abrogate TLR activity completely.  This could be accomplished by knocking 
out the vital adaptor molecules necessary for TLR signaling such as MyD88 and TRIF. 
Using knockout macrophages the protein induction response could be measured and 
analyzed.  This experiment that would give a broad knockout of TLR activity would 
setup further investigation into either specific TLR receptors or investigation into other 
classes of PRR’s as the source of recognition.
Looking forward: A potential adjuvant candidate
The finding that a modified T3SS needle is a PAMP recognized by the immune 
system is potentially useful for the design of an adjuvant product.  The protein is highly 
potent, producing 75% of the response to LPS in our PMA-activated human macrophage 
model despite the needle proteins being an order of magnitude less in molar 
concentration compared to LPS (Fig. 4B).   Stimulators of the innate immune system are 
important for aiding the adaptive immune system to recognize vaccine candidates as 
pathogenic through production of co-stimulatory molecules and cytokines (59).  An 
especially important effector between innate and adaptive immunity is the dendritic cell 
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(DC), and studying how the DC reacts to this PAMP would be especially interesting in 
further exploration of this protein as an adjuvant product.
Initial studies with DC’s and truncated YscF could start with measuring activation 
through pro-inflammatory cytokines, similar to our macrophage experiments.  Further 
investigation could involve conjugating the needle protein to a FACS-detectable label 
and measuring binding of the protein to the DC, which would allow quantification of 
binding as well as monitoring DC cell markers such as CD80 and CD86 to show 
maturation in response to the T3SS needle protein.   A good adjuvant candidate should be 
a potent inducer of innate immunity, have a highly reproducible response, and be non-
toxic to humans.  Alum-based products are the only adjuvants approved for human use, 
which unfortunately generate relatively weak cytotoxic T-cell responses.  Novel 
adjuvants that push the immune system towards cell-based and humoral immunity are 
needed for more effective vaccines (92).  Another bacterial protein, FliC or flagellin, has 
been shown to stimulate TLR5 and be recognized by the host as a PAMP (62).  After 
clarifying the mechanism of action of the protein, and showing mucosal adjuvant activity 
and a Th2 response from the immune system, clinical trials are now underway for 
flagellin-based vaccines (93). The precedent of a bacterial protein PAMP reaching 
clinical trials as an adjuvant aids in support of further characterization of trYscF and adds 
interest to its possible role as an adjuvant product.
Structure-function studies of YscF using site-directed mutagenesis should yield 
some interesting data.  The YscF needle protein is relatively small at 87 amino acids, so 
potential study of the protein in this way is realistic.  The most likely areas that are being 
recognized as a PAMP by the host are going to be highly conserved regions, and surface 
36
exposed.  The area adjacent to the turn between the two α-helices of the protein would be 
one target for mutagenesis.  This region is the minor epitope identified in previous work, 
and is also the region of the needle protein that putatively interacts with the tip of the 
needle (94).   Additionally, the C-terminal 5 amino acids are vital for polymerization of 
the protein (84), removal of those residues could give valuable information on the 
importance of the multimer in its inflammatory activity.  Alternatively, high molecular 
weight species of the needle protein could be isolated in the purification by size-
exclusion gel filtration as described in (40).  Using size-exclusion chromatography would 
allow exclusion or isolation of the high molecular weight needle protein, and allow 
experimentation without further truncation of the sample.  Studying the protein further to 
identify the exact region of PRR recognition would accomplish two things; it would 
allow experimentation with a truncated, innocuous form of YscF by changing the 
respective amino acid residues to benign substitutions.  This allows investigation into if 
the protein is more protective with a readily available immunogenic site, without its 
inflammatory properties.  Secondly, understanding the means of activation would support 
research into the protein as a potential adjuvant for vaccine work.
Besides the potential use as an adjuvant, truncated YscF would have a unique 
advantage in use as a multivalent recombinant Y. pestis vaccine due to its immunogenic 
and potential adjuvant properties.  Recombinant protein vaccines for Y. pestis would have 
the benefit of avoiding the severe side-effects that previous whole-cell killed vaccines, 
and live-attenuated EV76 vaccines have had on humans (95, 3).  A multivalent Y. pestis  
protein subunit vaccine provides some measure of protection against a terrorist 
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organization engineering a mutant protein around the immunological protection afforded 
by a recombinant subunit vaccine.
Looking forward, characterization of the modified YscF and its effect on the host 
bears merit both for its potential use as an adjuvant, and for its immunogenic properties in 
a Y. pestis vaccine.  Additionally, expanding this observation to other species that express 
T3SS opens the door to answering questions of T3SS biology, including yielding clues on 
the transmission of host-contact signal to the bacterium and evolution in the avoidance of 





Figure 7.  Murine bone marrow-derived macrophage protein induction.  Macrophages were seeded at 
a concentration of 2 x 105 cells/ml in DMEM supplemented with colony stimulating factor.  Protein 
induction was conducted with 1 µg/ml protein samples.  Macrophages were incubated with protein for 
5 hours before supernatant was collected for cytokine analysis by ELISA.  Graph is the results of one 
experiment, n=3. Error bars are S.E.M.
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Figure 8.  THP-1 monocyte with MxiH induction.  Monocytes were seeded at a concentration of 8 x 
105 cells/ml.  MxiH was applied at a concentration of 105nM and incubated for 5 hours before 
supernatant was collected for cytokine measurement.  Human TNF-α ELISA was used to measure 
cytokine release, and data was normalized compared to flagellin control.  Graph represents 3 
experiments, n=9.  Error bars are S.E.M.  Statistical significance determined by Tukey’s post-test.  *,p 
<0.05.
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Figure 9.  THP-1 monocyte protein induction at 24 hours.  Monocytes were seeded at 8 x 105 cells/ml. 
Protein was applied at a concentration of 1 µg/ml and incubated for 24 hours before supernatant was 
collected for cytokine measurement.  Human TNF-α ELISA was used to measure cytokine release. 
Graph is the result from one experiment, n=3.  Error bars represent S.E.M.  Statistical significance 
determined by Tukey’s post-test.  *, p<0 .05.
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